COVID-19

ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177

Garching / Munich, Germany and Indianapolis, IN, USA, July 31, 2023 –  ITM Isotope Technologies Munich SE (ITM), a leading…

1 year ago

ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177

GARCHING / MUNICH, Germany and INDIANAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- ITM Isotope Technologies Munich SE (ITM), a leading…

1 year ago

Globus Medical Announces Launch of the MARVEL™ Growing Rod System, the company’s first product designed specifically for early onset scoliosis

MARVEL™ is Globus Medical’s second major release this year in the pediatric scoliosis spaceAUDUBON, Pa., July 31, 2023 (GLOBE NEWSWIRE)…

1 year ago

Crinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly

Webinar Being Held on August 8, 2023 at 12:00 p.m. Eastern TimeSAN DIEGO, July 31, 2023 (GLOBE NEWSWIRE) -- Crinetics…

1 year ago

Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market

WALTHAM, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology…

1 year ago

Alignment Healthcare Spotlights Improved Senior Health Outcomes, Greater Access to Care in 2nd Annual ESG Report

Latest data details how Medicare Advantage company drove greater reduction in members’ blood sugar levels and diabetes-related deaths, provided more…

1 year ago

iCAD to Report Second Quarter 2023 Financial Results on August 14, 2023

NASHUA, N.H., July 31, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer…

1 year ago

Bionano Announces OGM Roadshow, TOUR, which Provides Education on the Company’s Workflow and Helps Build a Community of Users

SAN DIEGO, July 31, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the successful launch of its…

1 year ago

Taysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome

Independent Data Monitoring Committee recommended REVEAL Phase 1/2 trial continuation and proceeding with dosing of second patient based on encouraging…

1 year ago

Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS

89% and 84% of patients were maintained on ≥12- and ≥16-week dosing intervals, respectively, throughout the two-year period, while sustaining their…

1 year ago